论文部分内容阅读
目的探讨非小细胞肺癌的有效治疗方案,分析非小细胞癌的临床特点和相关的预后因素,以期提高临床疗效,为临床工作提供依据。方法 158例非小细胞肺癌患者,随机分为对照组与观察组,各79例。对照组只行多西他赛加顺铂药物化疗,观察组则在前者基础上行生物免疫疗法(DC-CIK)联合治疗。对两组患者的治疗效果、治疗前后患者的体重、睡眠时间、进食情况及心理状态等指标进行观察比较。结果观察组总有效率为88.6%,不良反应发生率为8.9%;对照组总有效率54.4%,不良反应发生率为22.8%,两组比较差异有统计学意义(P<0.05)。观察组治疗后各症状均少于对照组,差异有统计学意义(P<0.05)。结论采用DC-CIK联合化疗治疗非小细胞肺癌比单纯药物化疗效果更显著、安全性更好,并且能够明显改善患者预后情况,缓解患者痛楚,提高治疗成功率和患者生活质量,延长患者生存期,值得临床继续推广。
Objective To investigate the effective treatment of non-small cell lung cancer and to analyze the clinical features and related prognostic factors of non-small cell lung cancer in order to improve the clinical efficacy and provide the basis for clinical work. Methods A total of 158 patients with non-small cell lung cancer were randomly divided into control group and observation group, 79 cases each. In the control group, only docetaxel plus cisplatin was used in the control group, while the observation group received biologic immunotherapy (DC-CIK) in combination with the former. The therapeutic effect of two groups of patients before and after treatment, body weight, sleep time, eating status and psychological indicators were observed and compared. Results The total effective rate was 88.6% in the observation group and 8.9% in the adverse reaction group. The total effective rate in the control group was 54.4% and the adverse reaction rate was 22.8%. There was significant difference between the two groups (P <0.05). The symptoms of the observation group were less than those of the control group after treatment, the difference was statistically significant (P <0.05). Conclusions The treatment of non-small cell lung cancer with DC-CIK combined with chemotherapy is more effective and more safe than simple drug chemotherapy, and can significantly improve the prognosis of patients, alleviate the pain of patients, improve the success rate of treatment and quality of life of patients, prolong the survival of patients , It is worth to continue to promote clinical.